OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity vMYX-hIL-12/Dec produces functional ...
PHOENIX--(BUSINESS WIRE)--OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, has extended its intellectual property (IP) portfolio to include an exclusive option to license IP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback